|Slideshows|April 9, 2018

Asthma and Risk of Schizophrenia

Is there a link between childhood and parental asthma and risk of schizophrenia?

Newsletter

Receive trusted psychiatric news, expert analysis, and clinical insights — subscribe today to support your practice and your patients.

Subscribe

Related Content

Tips for Leveraging Motivational Interviewing in LAI Discussions in Schizophrenia

ByGerald A. Maguire, MD

July 12th 2026

Long-Acting Injectables in Schizophrenia: Closing the Gap Between Evidence and Practice

ByHeidi Anne Duerr, MPH

July 11th 2026

Building Trust in Schizophrenia Care: How the Therapeutic Alliance Shapes Outcomes

ByGerald A. Maguire, MD

July 11th 2026

Phase 2 Trial Initiated for Briumvi for Treatment-Resistant Schizophrenia

ByJessica Walters

July 6th 2026

Preventing Relapse in Schizophrenia: Focus on Women’s Mental Health

BySusan Hatters Friedman, MD, MSt, DFAPA,Ashley A. Mulvihill, MD

June 25th 2026

Latest CME

Video

(CME Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Gus Alva, MD, DFAPA; Ilan Melnick, MD

Video

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Jason Kellogg, MD; Gus Alva, MD, DFAPA; Melanie Barrett, MD; Yvette Elpidio, MSN, FNP-C

Video

Expert Illustrations & Commentary: Visualizing the Role of Novel Muscarinic Agents in the Management of Schizophrenia

Ilan Melnick, MD; Linda Collado, MD, DABPN, FAPA; Maria Collado, MD, FAPA

Video

Clear Skin, Clear Mind: Integrating Mental Health into Psoriasis Care

John Koo, MD; T.J. Chao, MPAS, PA-C

Video

Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Patricia Junquera, MD; Maria Collado, MD; Erin C. Crown, MHSPAS, PA-C, Psych-CAQ

Video

Expert Illustrations & Commentary: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Juan D. Oms, MD, FAPA; Linda Collado, MD, DABPN, FAPA; Ginger Shupe, MD

Video

(CPE Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Gus Alva, MD, DFAPA; Ilan Melnick, MD

Video

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Jason Kellogg, MD; Gus Alva, MD, DFAPA; Melanie Barrett, MD; Yvette Elpidio, MSN, FNP-C

Asthma and Risk of Schizophrenia

Related Content

Tips for Leveraging Motivational Interviewing in LAI Discussions in Schizophrenia

Long-Acting Injectables in Schizophrenia: Closing the Gap Between Evidence and Practice

Building Trust in Schizophrenia Care: How the Therapeutic Alliance Shapes Outcomes

Phase 2 Trial Initiated for Briumvi for Treatment-Resistant Schizophrenia

Preventing Relapse in Schizophrenia: Focus on Women’s Mental Health

Latest CME

(CME Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Expert Illustrations & Commentary: Visualizing the Role of Novel Muscarinic Agents in the Management of Schizophrenia

Clear Skin, Clear Mind: Integrating Mental Health into Psoriasis Care

Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Expert Illustrations & Commentary: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

(CPE Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Trending on Psychiatric Times

Vol 43, Issue 7 - Interactive

Beyond Deprescribing: A Formula for Excellent Clinical Care

AI Chatbots and the Erosion of Therapeutic Discomfort

Vagus Nerve Stimulation in Difficult-to-Treat Depression: When Does It Work Best?

Long-Acting Injectables in Schizophrenia: Closing the Gap Between Evidence and Practice